Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, April 12, 2023
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
[ Wed, Apr 12th 2023
] - WOPRAI
Tue, April 11, 2023
[ Tue, Apr 11th 2023
] - WOPRAI
[ Tue, Apr 11th 2023
] - WOPRAI
[ Tue, Apr 11th 2023
] - WOPRAI
[ Tue, Apr 11th 2023
] - WOPRAI
[ Tue, Apr 11th 2023
] - WOPRAI
[ Tue, Apr 11th 2023
] - WOPRAI
[ Tue, Apr 11th 2023
] - WOPRAI
[ Tue, Apr 11th 2023
] - WOPRAI
Uy Ear Reiterated (ARQT) at Strong Buy and Held Target at $61 on, Apr 11th, 2023
Uy Ear of Mizuho, Reiterated "Arcutis Biotherapeutics, Inc." (ARQT) at Strong Buy and Held Target at $61 on, Apr 11th, 2023.
Uy has made no other calls on ARQT in the last 4 months.
There are 3 other peers that have a rating on ARQT. Out of the 3 peers that are also analyzing ARQT, 0 agree with Uy's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Uy
- Gregory Fraser of "Truist Securities" Maintained at Strong Buy with Decreased Target to $45 on, Wednesday, March 29th, 2023
- Serge Belanger of "Needham" Maintained at Strong Buy with Decreased Target to $24 on, Thursday, March 16th, 2023
- Vikram Purohit of "Morgan Stanley" Maintained at Buy with Decreased Target to $50 on, Wednesday, March 1st, 2023
